Login to Your Account

Abridged Sutent Study, Afinitor Data Questioned Before ODAC

By Jennifer Boggs

Monday, April 11, 2011
Assuming an agreement between the House and the Senate halts a government shutdown, the FDA's Oncologic Drugs Advisory Committee is slated to meet Tuesday to review Pfizer Inc.'s Sutent (sunitinib) and Novartis AG's Afinitor, both of which are seeking expanded approval for pancreatic neuroendocrine tumors (pNET).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription